Pulmonary fibrosis patients experience significant practical and emotional problems from their disease, according to a nine-country Boehringer Ingelheim survey. More than 150 people took part in the survey, which exposed the worries that idiopathic pulmonary fibrosis patients have about their disease’s irreversible progression. Sixty-one percent of patients said they were either…
Pulmonary Fibrosis Patients Face Practical and Emotional Challenges, Survey Shows
Aquatic exercise can be very beneficial for patients with pulmonary fibrosis (PF), as the water supports a good proportion of a person’s body weight, making it easier to move around. The American Physiotherapy Association has some recommended exercises to try next time you’re in the pool: MORE: Tips…
Last week I had the privilege of doing a live video, via Pulmonary Fibrosis News’ Facebook page. It was a lot of fun to have so many patients, caregivers and medical professionals tune in as we talked about treatment. The beauty of a…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SM04646, a therapy developed by San Diego-based Samumed to treat idiopathic pulmonary fibrosis (IPF). This designation provides several benefits, including tax incentives, exemption from the FDA user fee and potential market exclusivity for seven years following approval. SM04646,…
The definition of patient advocacy can vary from patient to patient, and can include many different roles for those involved in any type of chronic illness advocacy campaign or project. What also varies is the patients’ comfort level when getting involved in different initiatives that might focus on…
Idiopathic pulmonary fibrosis (IPF) is a progressive chronic lung condition which affects people both emotionally and physically. The Food and Drug Administration (FDA) held a patient-focus drug development initiative where people living with IPF could talk freely about the effect the disease has on their everyday lives. Here’s…
Ofev (nintedanib) can counter lung fibrosis by correcting abnormalities in lung blood-vessel structure, according to a German study in mice. The research suggests that fibrosis, or tissue scarring, and mechanisms involved in blood vessel formation interact in the progression of the disease. Researchers at the Johannes Gutenberg University Medical Center in Mainz studied…
ZappRx’s new digital platform for prescribing specialty medications, including therapies to treat pulmonary fibrosis, can now be used at two centers with expertise in respiratory conditions —  Arizona Pulmonary Specialists and Harbor-UCLA Medical Center. The platform was designed to speed up and simplify the complex process required to order…
We know dealing with pulmonary fibrosis sometimes feels like an uphill battle, both for the patients and the caregivers. You feel like you’re not doing enough or as if the disease is taking up all your time and attention. To help you on your journey, we’ve gathered a few quotes we…
Patients with idiopathic pulmonary fibrosis (IPF) prescribed Ofev (nintedanib) or Esbriet (pirfenidone) in real-world practice have shown similar tolerability and adverse event profiles as those reported in large-scale clinical trials testing these drugs, according to recent research. For many decades, IPF treatment was limited to supportive care…
